 NEW HAVEN, Conn., Sept. 07, 2022 GLOBE NEWSWIRE -- BioXcel Therapeutics, Inc. Nasdaq: BTAI, a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 10:30 a.m. Eastern Time. Management will discuss the Companys neuroscience and immuno-oncology programs as well as its artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process. They will also discuss the Companys commercial launch strategy for IGALMITM dexmedetomidine sublingual film. 